Fabry Disease: Clinical Trials

19 trials for Fabry Disease, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

19 completed. 19 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	19	Completed 19

Follow Fabry Disease: new trials by email Literature Review of Fabry Disease trials Research Report on Fabry Disease

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease Recombinant human alpha galactosidase A (agalsidase beta), Recombinant human alpha-galactosidase A (agalsidase beta) - Fabry Disease	Phase 3	Completed	Bio Sidus SA	20	2022-12-13	2026-02-18
A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease REPLAGAL - Fabry Disease	Phase 3	Completed	Takeda	20	2022-05-01	2024-10-08
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease migalastat HCl 150 mg - Fabry Disease	Phase 3	Completed	Amicus Therapeutics	16	2019-10-11	2026-02-05
A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease Lucerastat - Fabry Disease	Phase 3	Completed	Idorsia Pharmaceuticals Ltd.	107	2018-12-18	2026-11-02
Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients pegunigalsidase alfa - Fabry Disease	Phase 3	Completed	Chiesi Farmaceutici S.p.A.	29	2018-11-13	2026-05-22
Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years) Migalastat HCl 150 mg - Fabry Disease	Phase 3	Completed	Amicus Therapeutics	22	2018-09-27	2021-11-30
Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease pegunigalsidase alfa - Fabry Disease	Phase 3	Completed	Chiesi Farmaceutici S.p.A.	97	2018-09-16	2026-03-24
Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease Lucerastat, Placebo - Fabry Disease	Phase 3	Completed	Idorsia Pharmaceuticals Ltd.	118	2018-06-21	2024-08-09
Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks Pegunigalsidase alfa - Fabry Disease	Phase 3	Completed	Protalix	30	2017-07-10	2023-09-13
Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa) PRX-102 (pegunigalsidase alfa) - Fabry Disease	Phase 3	Completed	Protalix	22	2017-05-17	2023-09-13
Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function PRX-102 (pegunigalsidase alfa), agalsidase beta - Fabry Disease	Phase 3	Completed	Protalix	78	2016-06-01	2023-09-13
Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease migalastat HCl 150 mg - Fabry Disease	Phase 3	Completed	Amicus Therapeutics	84	2015-03-14	2020-12-21
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease migalastat hydrochloride, agalsidase - Fabry Disease	Phase 3	Completed	Amicus Therapeutics	68	2011-09-08	2018-11-01
A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease agalsidase alfa - Fabry Disease	Phase 3	Completed	Shire	171	2011-08-10	2021-06-08
Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease Replagal - Fabry Disease	Phase 3	Completed	Shire	35	2010-04-13	2021-06-08
Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease migalastat hydrochloride, Placebo - Fabry Disease	Phase 3	Completed	Amicus Therapeutics	67	2009-10-23	2018-10-30
Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease Replagal - Fabry Disease	Phase 3	Completed	Shire	44	2008-12-29	2021-06-09
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms Agalsidase beta - Fabry Disease	Phase 3	Completed	Genzyme, a Sanofi Company	31	2008-09-01	2016-06-29
A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease Fabrazyme (agalsidase beta) - Fabry Disease	Phase 3	Completed	Genzyme, a Sanofi Company	58	1999-10-01	2013-12-04

Narrower conditions

Broader conditions

Interventions

Sponsors

Countries

Results publications

NIH funding